scholarly journals Pathogenesis of malignant ascites in ovarian cancer patients

2004 ◽  
Vol 12 (2) ◽  
pp. 115-118 ◽  
Author(s):  
Zorica Stanojevic ◽  
Gorana Rancic ◽  
Stojan Radic ◽  
Natasa Potic-Zecevic ◽  
Biljana Djordjevic ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Peritoneal Cavity ◽  
Malignant Disease ◽  
Prognostic Significance ◽  
Malignant Ascites ◽  
Malignant Cells ◽  
Stage Disease ◽  
New Treatment ◽  
End Stage

Peritonitis carcinomatosa, indicating the presence of malignant cells in the peritoneal cavity, is a well- known complication of malignant disease. The collection of intraperitoneal fluid in a patient with ovarian cancer is most likely due to intraperitoneal spread of disease. The recognition of small quantities of intraperitoneal fluid may have staging and prognostic significance, while symptomatic large collections may reflect end-stage disease, which permits only palliative therapeutic options. In this paper we dis- cussed the pathogenesis of malignant ascites in ovarian cancer patients and suggested potential new treatment approaches.

scholarly journals Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Ann Rita Halvorsen ◽  
Gunnar Kristensen ◽  
Andy Embleton ◽  
Cybil Adusei ◽  
Maria Pilar Barretina-Ginesta ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Prognostic Significance ◽  
Response To Treatment ◽  
Rank Test ◽  
Specific Marker ◽  
High Grade ◽  
Standard Chemotherapy ◽  
Validation Set ◽  
Serous Tumors

Ovarian cancer patients are recognized with poor prognosis. This study aimed to identify microRNAs in plasma for predicting response to treatment and outcome. We have investigated microRNAs in plasma from ovarian cancer patients enrolled in a large multicenter study (ICON7), investigating the effect of adding bevacizumab to standard chemotherapy in patients diagnosed with epithelial ovarian cancer. Patients with different histology, grade, and FIGO stages were included (n=207) in this study. Screening of 754 unique microRNAs was performed in the discovery phase (n=91) using TaqMan Low Density Arrays. The results were validated using single assays and RT-qPCR. Low levels of miR-200b, miR-1274A (tRNALys5), and miR-141 were significantly associated with better survival, confirmed with log-rank test in the validation set. The level of miR-1274A (tRNALys5) correlated with outcome was especially pronounced in the high-grade serous tumors. Interestingly, low level of miR-200c was associated with 5-month prolongation of PFS when treated with bevacizumab compared to standard chemotherapy. We found prognostic significance of miR-200b, miR-141, and miR-1274A (tRNALys5) in all histological types, where miR-1274A (tRNALys5) may be a specific marker in high-grade serous tumors. The level of miR-200c may be predictive of effect of treatment with bevacizumab. However, this needs further validation.

8040 POSTER Diagnostic and Prognostic Significance of CA125 and HE4 in Ovarian Cancer Patients

2011 ◽  
Vol 47 ◽  
pp. S539
Author(s):  
E. Bandiera ◽  
C. Romani ◽  
C. Specchia ◽  
L. Zanotti ◽  
S. Belloli ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Prognostic Significance

Prognostic significance of tumor necrosis in ovarian cancer patients treated with neoadjuvant chemotherapy and interval surgical debulking

2006 ◽  
Vol 16 (3) ◽  
pp. 986-990 ◽  
Author(s):  
T. Le ◽  
P. Shahriari ◽  
L. Hopkins ◽  
W. Faught ◽  
M. Fung Kee Fung
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Tumor Necrosis ◽  
Residual Disease ◽  
Prognostic Significance ◽  
Tumor Grade ◽  
Predictive Variables ◽  
Surgical Debulking ◽  
Optimal Debulking

The objective of this study was to study the significance of tumor necrosis documented at the time of interval surgical debulking after neoadjuvant chemotherapy. Retrospective chart reviews were carried out from 1997 to 2005 to identify ovarian cancer patients treated with neoadjuvant chemotherapy. Patients' demographics together with disease characteristics, treatment-related variables, and outcomes were recorded. Cox proportional hazard models were built to model time to progression using predictor variables such as age, cancer stage, tumor grade, residual disease, percentage change in CA125 level from baseline, and degree of necrosis in resected tumor specimens. One hundred one patients were included in the study. Optimal debulking was achieved in 74% of the patients. Cox regressions revealed three significant predictive variables of time to first progression: younger age (hazard ratio [HR] = 0.95, 95% CI 0.92–0.98, P = 0.004), residual disease (P = 0.048), and the absence/minimal tumor necrosis after three cycles of neoadjuvant chemotherapy (HR = 1.97, 95% CI 1.01–3.87, P = 0.048). The estimated median survival was 50.66 months (95% CI 46.12–55.20). The lack of or minimal tumor necrosis after neoadjuvant chemotherapy is an independent risk factor for recurrent disease.

Antibody Immunity to the p53 Oncogenic Protein Is a Prognostic Indicator in Ovarian Cancer

2006 ◽  
Vol 24 (5) ◽  
pp. 762-768 ◽  
Author(s):  
Vivian Goodell ◽  
Lupe G. Salazar ◽  
Nicole Urban ◽  
Charles W. Drescher ◽  
Heidi Gray ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Tumor Antigens ◽  
Enzyme Linked Immunosorbent Assay ◽  
Advanced Stage ◽  
Topoisomerase Iiα ◽  
P53 Antibodies ◽  
Stage Disease ◽  
Her 2

Purpose Presence of intratumoral T-cell infiltration has been linked to improved survival in ovarian cancer patients. We questioned whether antibody immunity specific for ovarian cancer tumor antigens would predict disease outcome. We evaluated humoral immune responses against ovarian cancer antigens p53, HER-2/neu, and topoisomerase IIα. Patients and Methods Serum was collected from 104 women (median age, 59 years; range, 34 to 89 years) at the time of their initial definitive surgery for ovarian cancer. Serum was analyzed by enzyme-linked immunosorbent assay for antibodies to p53, HER-2/neu, and topoisomerase IIα proteins. Antibody immunity to tetanus toxoid was assessed as a control. The incidence of humoral immunity at the time of diagnosis to any of these three antigens was tabulated. For patients with advanced-stage disease (III/IV), correlation was made between the presence of tumor-specific immunity at the time of diagnosis and overall survival. Patients were followed for a median of 1.8 years. Results Multivariate analysis showed the presence of p53 antibodies to be an independent variable for prediction of overall survival in advanced-stage patients. Overall survival was significantly higher for patients with antibodies to p53 when compared with patients without p53 antibodies (P = .01). The median survival for p53 antibody-positive patients was 51 months (95% CI, 23.5 to 60.5 months) compared with 24 months (95% CI, 19.4 to 28.6 months) for patients without antibodies to p53. Conclusion Data presented here demonstrate that advanced stage ovarian cancer patients can have detectable tumor-specific antibody immunity and that immunity to p53 may predict improved overall survival in patients with advanced-stage disease.

scholarly journals Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients

BMC Cancer ◽  
2011 ◽  
Vol 11 (1) ◽  
Author(s):  
Denis Lane ◽  
Isabelle Matte ◽  
Claudine Rancourt ◽  
Alain Piché
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Prognostic Significance

scholarly journals Incidence and Prognostic Significance of Liver Metastases for Newly Diagnosed Ovarian Cancer in Relation to Subtypes

2021 ◽  
Author(s):  
Ying Zhu ◽  
Yifang Zhang ◽  
Lingyun Zhai ◽  
Zhigang Zhang ◽  
Jianwei Zhou
Keyword(s):  
Ovarian Cancer ◽  
Liver Metastasis ◽  
Liver Metastases ◽  
Cancer Patients ◽  
Cancer Metastasis ◽  
Cox Regression ◽  
Prognostic Significance ◽  
Newly Diagnosed ◽  
Histological Types ◽  
Visceral Organs

Abstract Background: Ovarian cancer is a heterogeneous and aggressive malignant tumor, and the liver is one of the most common metastases target visceral organs of ovarian cancer. We aim to analysis the incidence and prognostic relevance of histological subtypes for patients with liver metastases in newly diagnosed ovarian cancer. Methods: In the Surveillance, Epidemiology, and End Results (SEER) database, we identified the ovarian cancer patients from 2010 to 2016. Multivariable logistic regression was used to determine whether histological types were associated with the presence of liver metastases at diagnosis. The Kaplan-Meier method and multivariable Cox regression was performed to identify covariates associated with survival using the histological types. Results: Among 25293 ovarian cancer patients, 1749 cases presented with liver metastases. The incidence proportions were highest among ovarian carcinosarcoma patients (OR=17.76, 95% CI=9.26-34.09), and liver metastasis specificity was the highest in the clear cell type (70.69% of the metastatic subset). The median cancer-specific survival (CSS) for non-metastatic ovarian cancer patients was 77 months, but the ovarian cancer with only liver metastasis was 21 months. The mucinous (5 months; vs nonepithelial subtype, HR=0.26; 95% CI, 0.14-0.49) subtype experienced the shortest median survival among all histologic types. Conclusion: This population-based study provides that liver was one of the most common distant visceral organs for ovarian cancer metastasis, and the incidence proportions of liver metastasis were highest for carcinosarcomas subtype, and the mucinous ovarian cancer with liver metastasis being associated with the poorest survival.

Sign in / Sign up

Export Citation Format

Share Document